Articles tagged with Cancer
A study reveals how colorectal tumors use TGF-β to prevent immune cells from reaching and attacking the tumor. The researchers suggest strategies to improve immunotherapy efficacy by blocking this dual barrier and identifying new therapeutic targets.
Recent research in pathological foundation models has demonstrated robust representation learning capabilities and generalization performance. These models enable multi-task transfer with minimal data, significantly enhancing clinical utility and generalizability.
The University of Freiburg is witnessing a surge in interdisciplinary research success with the recent awarding of four Synergy Grants from the European Research Council. Prof. Dr. Stefan Glunz's project aims to develop resource-efficient photovoltaic technologies, while Prof. Dr. Claudine Kraft's project investigates the degradation o...
The study found that a nine-month programme of supervised exercise improved muscle mass and strength, particularly in the arms and legs, and physical performance in patients with breast cancer that had spread to other parts of the body. Muscle mass increased by an average of 0.79 kg after three months and 0.32 kg after six months compa...
Researchers from Università Cattolica del Sacro Cuore develop hybrid endoscopes combining diagnostic and therapeutic functions. The MULTIPROBE project aims to revolutionize cancer care by providing a combined diagnostic and therapeutic tool using innovative endoscopic systems and cold plasma therapy.
Despite progress in controlling stomach, liver, and esophageal cancers, China's total cancer deaths continue to rise, projected to reach 2.4 million by 2030. Population aging and unequal access to healthcare drive these increases, with rural areas lagging behind urban regions.
Dr. Lovly brings nearly two decades of experience in clinical care, research and academic leadership to her new role, shaping the modern landscape of lung cancer care. Her expertise in precision medicine will be instrumental in accelerating progress for patients with lung cancer across the country.
The ABC Global Decade Report 2015-2025 reveals significant advances in breast cancer care for some patients globally. However, persistent inequalities leave many behind. The report's findings drive the creation of the ABC Global Charter 2025-2035, aiming to improve equitable progress and transform care for everyone with ABC.
Researchers have discovered a new way to understand cancer and its vulnerabilities by targeting FSP1, a protein that helps cancer cells survive. The study found that FSP1 inhibitors can effectively reduce the growth of metastatic melanoma cells in lymph nodes.
A recent study published in The FEBS Journal found that specific gut bacteria can efficiently metabolize different forms of nitrogen, preventing carcinogenic nitrosamine formation. This process is critical for maintaining intestinal and systemic health, potentially decreasing the risk of certain cancers.
A global survey of nearly 4,000 young women with advanced breast cancer found that nearly half have children under 18 and face significant hardship. The study also revealed delays in seeking care, unmet psychosocial needs, and limited access to precision diagnostics.
Researchers at University of Miami Miller School of Medicine have developed a new combination therapy that shrinks tumors, reduces cancer stem cells and reprograms immune environment to combat hormone-resistant breast cancer. The triple therapy approach targets tumor-associated macrophages, which act like bodyguards for cancer cells.
Researchers from Arc Institute, UCSF, and Fred Hutchinson Cancer Center identified PTGES3 as a key regulator of the androgen receptor in prostate cancer. The study found that PTGES3 contributes to tumor growth and suggests it could be a promising new target for treating aggressive prostate cancers.
A study of over 60,000 US patients with advanced breast cancer found average survival times increased by six to seven months since 2011. Researchers attribute the improvement to more effective treatments, wider diagnosis, and quality of care advancements.
A new case report describes the successful treatment of a 37-year-old woman with HER2-positive breast cancer that had spread to the membranes surrounding the brain and spinal cord. Trastuzumab deruxtecan, an antibody-drug conjugate, improved the patient's neurological symptoms and reduced cancer growth.
Researchers at Syracuse University have developed a novel method using ultrasound to trigger chemotherapy drugs in targeted areas, minimizing damage to healthy tissues. The approach could lead to safer and more effective cancer treatment, potentially reducing side effects and improving patient outcomes.
The National Comprehensive Cancer Network (NCCN) has expanded access to cancer treatment in Sub-Saharan Africa with new international adaptations. The adaptations reflect significant progress in cancer care delivery, including increased access to imaging techniques and biomarker testing.
Scientists at Wake Forest University School of Medicine have discovered a new way to kill cancer cells by blocking their ability to clean up harmful waste. By inhibiting peroxiredoxin-3, researchers found that toxic levels of hydrogen peroxide overwhelm cancer cells, destroying them.
A large global study of 23,000 people found that proton pump inhibitors (PPIs) used for indigestion and heartburn were associated with poorer overall survival and a higher risk of severe side effects in patients with breast cancer. Statins and metformin showed no significant impact on either survival or adverse events.
A new editorial highlights the importance of primary care in preventing heart disease in breast cancer survivors. The study found that most women do not go on to develop serious cardiac disease, but those with higher-risk chemotherapy, older age, or multiple cardiovascular risk factors may benefit from closer monitoring.
Researchers have identified a new histone variant, macroH2A1.1, as a potential therapeutic target for treating Acute Myeloid Leukaemia. The study found that targeting this variant is safe for patients and may lead to new treatment options.
Researchers at Texas A&M University found that indoor hydroponic gardening significantly improves mental well-being, reduces depression levels, and enhances overall quality of life in cancer patients. Participants experienced improvements in emotional and social functioning after just eight weeks of gardening.
A UT Dallas team developed an electrochemical biosensor that accurately identifies eight volatile organic compounds linked to thoracic cancers. AI analysis enhances the accuracy of breath samples, showing promise for early lung cancer detection and improved patient outcomes.
Researchers at TUM have discovered a new regulatory mechanism that controls apoptosis, with potential applications in cancer treatment and neurodegenerative diseases. The study found that the protein VDAC1 can bind to Bcl-xL, promoting apoptosis.
The DEFEND study aims to assess whether virtual exercise sessions can be successfully delivered to patients with cancer receiving chemotherapy. Researchers will evaluate the impact on physical function, fatigue, and disability.
MIT researchers use messenger RNA to activate an immune pathway in nearby immune cells, triggering the destruction of tumors. The approach combines existing immunotherapy drugs and avoids side effects associated with large doses of STING activators.
Researchers at Mass General Brigham have developed a strategy to promote antitumor immunity by inducing cancer cells to produce an immune-activating molecule. This approach was shown to reduce tumor growth and improve survival in mouse models of aggressive melanoma, with potential applications beyond cancer therapies.
A UC Merced biologist found that activating neural signals can selectively remove cancer symptoms in planarian flatworms, which could change how doctors treat cancer and age-related diseases. The study may also shed light on degenerative conditions linked to aging.
A UCLA study finds that DNA copy-number changes enable melanoma cells to resist immune attacks, leading to tumor relapse. The researchers suggest a strategy to make tumors more prone to self-destruction after immune attacks, potentially extending the effectiveness of immunotherapy.
MIT researchers have developed new nanoparticles that deliver the immune-stimulating molecule IL-12 directly to ovarian tumors, eliciting a strong response and clearing tumors in over 80% of mice. This treatment combines with checkpoint inhibitors to launch an attack on cancer cells without causing side effects.
Research suggests m⁶A modification regulates oncogenic pathways, immune evasion, and metabolic reprogramming in cancer. Dysregulation of m⁶A drives cancer hallmarks like uncontrolled proliferation and metastasis.
The USF Health Institute for Translational Virology and Innovation advances research on viral diseases, virus-associated cancers, and pandemic pathogens. The institute focuses on understanding the mechanisms of viruses causing tumors and developing comorbidities in HIV patients.
Researchers found that baseline Anti-Mullerian Hormone (AMH) levels between 2.1-2.8 ng/ml correspond to 35-42% of live birth rates in women with cancer using fertility preservation. The study aims to improve prediction and standardization for fertility treatments.
A new study from UC San Diego found that clinical pharmacists can play a crucial role in helping people with cancer and diabetes better manage their blood sugar. The study showed that patients referred to a diabetes management and education clinic led by pharmacists saw meaningful improvements in blood sugar levels over time.
A new study suggests that collecting and testing cancer cells in patients' blood could help doctors choose the right breast cancer treatment. The 'labyrinth chip' technology separates cancer cells from other blood cells, allowing researchers to identify biomarkers that distinguish aggressive treatments from less invasive ones.
Dr. Jonathan D. Licht, a renowned expert in blood cancer and epigenetics, will succeed Peter A. Jones as the next president and chief scientific officer of Van Andel Institute. Licht's extensive research experience and leadership skills will further strengthen the Institute's efforts to improve health and lives.
Artificial intelligence is transforming cancer prevention, detection, and treatment by connecting technology with people. AI-driven public-health analytics, patient-doctor relationships, and diverse clinical research are crucial for delivering immediate benefit to patients, clinicians, and policymakers.
A research team has identified a molecule that can prevent the onset of peripheral neuropathies caused by chemotherapy, which are common and persistent neurological complications. The molecule promotes cellular energy production and nerve cell resilience, reducing painful symptoms without affecting cancer treatment.
Researchers at Mayo Clinic have found a way to enhance the body's 'first responder' cells, which can boost standard immunotherapies for cancer. By targeting these myeloid cells, it may be possible to improve treatments that interfere with immune suppressive proteins PD-1 and PD-L1.
A study by Wake Forest University School of Medicine reveals that a stress response in immune cells contributes to chemotherapy-induced nerve damage. By blocking this pathway, researchers aim to develop new treatments to protect cancer patients from debilitating side effects.
Researchers at Cincinnati Children's discovered a specific gene mutation in 'cold' tumors that block immune checkpoint inhibitors. Rapamycin was found to make these tumors responsive again by inhibiting mTORC1 signaling.
Researchers discovered a unique protein in bowhead whales that repairs damaged DNA, potentially contributing to their remarkable longevity. The protein, CIRBP, is present at 100-fold higher levels in bowhead whales compared to other mammals.
Researchers developed a computational platform to design synthetic protein receptors that can detect tumor signals and boost T cell activity. The new receptors, called T-SenSERs, showed improved tumor control and longer survival in mouse models of lung cancer and multiple myeloma.
A Johns Hopkins-led study has found that two analgesic drugs, bupivacaine and rimegepant, can slow the growth of osteosarcoma tumors by inhibiting nerve signaling. The researchers tested these medications in mice with osteosarcoma-like tumors and observed a significant reduction in tumor growth and spread.
Cancer Communications, a new journal published through the AAAS Science Partner Journal program, aims to bridge global oncology insights and clinical impact. The journal welcomes submissions on various cancer research topics, including clinical trials, epidemiology, and molecular biology.
The Mays Cancer Center stands among the nation's leading institutions recognized for excellence in cancer care and research. It is one of only four NCI-designated Cancer Centers in Texas, offering specialized programs and delivering comprehensive, multidisciplinary care supported by clinical research.
Researchers have developed vitamin-engineered nanoplatforms that can overcome tumor heterogeneity and therapeutic resistance. These platforms integrate immunomodulation, precision drug delivery, and diagnostic capabilities, enabling targeted therapy and early detection of cancer.
Scientists have identified a new biomarker, F2R, which could improve ovarian cancer diagnosis and treatment. Elevated F2R levels are associated with shorter life spans, making it a valuable prognostic indicator.
The WNT signaling pathway is a double-edged sword in human health, promoting tumor growth and resistance to therapy while offering therapeutic targets. Recent advances in understanding this pathway aim to harness it for cancer treatment, with focus on improving drug specificity and combination therapies.
Recent review article highlights how single-cell multi-omics technologies are deciphering the intricate heterogeneity of biliary tract cancers. Researchers can now analyze genetic, transcriptomic, and epigenetic facets of individual cells within a tumor.
The intra-tumoral microbiome influences cancer initiation, progression, and immune regulation through various mechanisms. Targeting the tumor microbiota holds promise for precision medicine and cancer therapy.
A recent randomized controlled pilot study suggests that Baduanjin, a traditional Chinese mind-body exercise, may help alleviate menopausal symptoms and fatigue in breast cancer patients undergoing aromatase inhibitor therapy. The study found significant improvements in joint pain and cognitive/mood dimensions of fatigue.
Researchers at Hebrew University of Jerusalem have created a new type of drug molecule that can precisely destroy TERRA, an RNA molecule helping certain cancer cells survive. The discovery paves the way for a new generation of RNA-based cancer treatments targeting genetic roots rather than symptoms.
Scientists have characterized lipid nanoparticles' internal shape and structure, which correlates with how well they deliver therapeutic cargo. The research provides a blueprint for engineering more effective RNA therapies by matching LNP designs to specific therapies and tissues.
Researchers have uncovered a new mechanism by which the body's immune system responds to viral infections, potentially leading to a new approach for fighting cancer. The study reveals that infected cells produce their own unique RNA signal, Z-RNA, which sets off a chain reaction leading to cell death before viruses can hijack them.
A blood test detecting tiny fragments of cancer DNA can help tailor chemotherapy to individual patients with stage 3 colon cancer. The DYNAMIC-III study found that patients with low-risk levels had an 87% cancer-free rate three years after surgery, while those with high-risk levels had a much higher risk of recurrence.
A study by researchers at Umeå University found that high levels of HIF2α protein can reduce tumour growth and promote maturation of neuroblastoma cells. The findings challenge previous views on the role of HIF2α in cancer development.
Researchers use mathematical modeling to estimate how vaccination, screening, and treatment collectively drive elimination. Studies show that with sustained investment and policy coordination, cervical cancer could be eliminated within decades in high-income countries and within the next century globally. The models also reveal cost-ef...
UofL Health – Brown Cancer Center oncologists and researchers will continue developing novel therapies using patients' own immune system to defeat cancer. The center's faculty and research facilities support clinical trials that bring new treatments to patients.
The Mount Sinai Tisch Cancer Center has been named a Comprehensive Cancer Center by the National Cancer Institute, recognizing its breadth and depth of cancer research, clinical excellence, and commitment to health equity. The center will receive over $3 million annually in funding to support its research and innovation.